Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Site License Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use Datamonitor, July 2002, Pages: 42   Description     Table of Contents        Enquire before Buying    Send to a Friend   With CML’s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis’ Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market. - Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis. - Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010. - Assesses the CML market’s future based on the attention that Gleevec has provided and where the attention will likely move in the future. Genta/Aventis’ Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents. Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position. The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias.Access insights into the developmental gains available through CML and into the path to a successful revenue stream. Identify how targeting CML can provide significant sales gains through off-label usage in AML. Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development. Customers who bought this item also bought Chronic Leukemias - Curative Intent Raises The Bar Acute Myeloid Leukemia: Cytarabine Here to Stay Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets Niche Cancers 2001: Acute Myeloid Leukemia Acute Leukemias - Persistent Unmet Needs Confer Significant Commercial Opportunity Healthcare Review: Cancer - October 2002 Strategic Outlook On Protein Kinase Inhibitors in Oncology Antimicrobial resistance: Resistance drives a mature

		Top of page

All rights reserved. Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster